Login / Signup

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.

Thomas W LycanTimothy S PardeeWilliam J PettyMarcelo BonomiAngela AlistarZanetta S LamarScott IsomMichael D ChanAntonius A MillerJimmy Ruiz
Published in: PloS one (2016)
Single agent CPI-613 had no efficacy in this study. Further study of CPI 613 in combination with a topoisomerase inhibitor is warranted.
Keyphrases
  • clinical trial
  • phase ii
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • stem cells
  • randomized controlled trial
  • diffuse large b cell lymphoma
  • mesenchymal stem cells
  • multiple myeloma
  • phase iii